Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Total Current Liabilities (2016 - 2025)

AC Immune has reported Total Current Liabilities over the past 11 years, most recently at $118.5 million for Q4 2025.

  • Quarterly Total Current Liabilities rose 2.93% to $118.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $118.5 million through Dec 2025, up 2.93% year-over-year, with the annual reading at $118.5 million for FY2025, 2.93% up from the prior year.
  • Total Current Liabilities was $118.5 million for Q4 2025 at AC Immune, down from $122.9 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $21.7 billion in Q4 2021 and troughed at $11.6 million in Q1 2023.
  • The 5-year median for Total Current Liabilities is $113.1 million (2024), against an average of $3.9 billion.
  • Year-over-year, Total Current Liabilities skyrocketed 139962.65% in 2021 and then crashed 99.95% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $21.7 billion in 2021, then plummeted by 99.95% to $11.9 million in 2022, then skyrocketed by 128323.97% to $15.3 billion in 2023, then plummeted by 99.25% to $115.1 million in 2024, then increased by 2.93% to $118.5 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Total Current Liabilities are $118.5 million (Q4 2025), $122.9 million (Q3 2025), and $119.5 million (Q2 2025).